The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Novartis
Approval Status: Approved March 1998
Treatment for: second-line treatment of hypertension
General Information
Diovan HCT has been approved for second-line treatment of hypertension. Diovan HCT is a combination of an angiotensin II receptor blocker (ARB)--a first line treatment that lowers blood pressure with an overall incidence of side effects comparable to placebo--and a diuretic, which is commonly used with other therapies to provide additional blood pressure lowering.
